Glomerulonephritis (GN) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of disease-modifying therapies and the increasing prevalence of the disease. Only symptomatic treatments such as antihypertensives, corticosteroids, and diuretics are majorly prescribed, which help in treating high blood pressure, inflammation, and edema, respectively. Kidney biopsy is the major diagnostic measure used by the U.S. physicians to diagnose the disease; however, patients often remain undiagnosed until the endstage of renal disease due to late appearance of the symptoms. The development of new diagnostics and novel therapies, both from big and small pharmaceutical companies, is anticipated to have a positive impact on GN management. These innovative novel therapies will be able to command high prices, but their commercial success could be determined by how they will be adopted into medical practice.
- What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of glomerulonephritis?
- How are U.S. nephrologists treating glomerulonephritis patients?
- What medications are being utilized?
- What are the drivers determining prescribing practices for glomerulonephritis?
- What attributes should a new therapy show in order to be successful in the management of the disease?
- Geography: United States
- Primary research survey of 101 U.S. nephrologists
- Key drugs / drug classes covered: Corticosteroids, antihypertensive agents, diuretics, alkylating agents, antiproliferative agents, calcineurin inhibitors, Rituxan, fish oil products, etc.
- Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers of treatment selection.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
- Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Glomerulonephritis US August 2019
Author(s): Rohit Bansal, MS (Pharm.)
Rohit joined Decision Resources Group (DRG)’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team in April 2019. His current focus includes non-alcoholic steatohepatitis (NASH), glomerulonephritis, and renal anemia. Prior to joining DRG, Rohit worked as analyst helping pharmaceutical clients address their business questions across various therapeutic areas. Rohit’s postgraduate research centred on molecular dynamics. His work included computer-aided drug design software that involved studying the effect of pharmaceutical excipients on the reabsorption of drug molecules from cancer cells leading to drug resistance.